The European Medicines Agency (EMA), which acts as the pharmacovigilance authority in the European Union, is expected to issue a marketing authorization for a new type of coronavirus developed by Pfizer in the US and BioNTech in Germany. Frankfurter Allgemeine Zeitung (FAZ).
A press conference was held in Berlin in conjunction with reports indicating German government and European Union funds in Brussels. Jens Span The German Federal Health Minister, who indirectly confirmed the information, said it was “very good news” for the entire European Union that the EMA investigation could be completed by December 23.
He stressed that, by applying the same EU rule that applied to the United Kingdom, Germany or any other member state more affluent in Western Europe, it would have acted nationwide to allow, buy and use the vaccine, but within twenty weeks they chose the path of solidarity.
He said vaccinations will not start in Germany more than three to four days after the EMA permit is issued.
(MTI)
